- Avant Technologies (OTCQB: AVAI) and Ainnova Tech are finalizing a cost-effective automated retinal camera prototype.
- The device integrates with Ainnova's Vision AI platform, identifying diseases such as diabetic retinopathy and glaucoma.
- Global licensing rights are held by Ai-nova Acquisition Corp., a joint venture of Avant and Ainnova.
Avant Technologies, Inc. (OTCQB: AVAI) and Ainnova Tech, Inc. are in the final stages of developing a pioneering, low-cost automated retinal camera. This device will seamlessly integrate with Ainnova's Vision AI platform, automatically capturing and uploading retinal images, which the AI software then analyzes to produce risk reports in seconds.
The Vision AI software is capable of detecting a range of diseases, including diabetic retinopathy, glaucoma, macular edema, and cardiovascular disease, among others. While Vision AI is currently compatible with any fundus camera, the new proprietary device aims to offer a user-friendly and economical solution to enhance market entry and penetration.
The development of this new technology is facilitated through Ai-nova Acquisition Corp. (AAC), a joint venture between Avant and Ainnova, which holds the global licensing rights for developing, maintaining, and marketing Ainnova's technology portfolio. This strategic move positions the joint venture to capture a significant market share by overcoming the cost barrier associated with traditional fundus cameras.
Currently, the device is in the prototype phase, with plans for full-scale development underway. This advance aims to expedite patient referrals and broaden disease detection beyond diabetic conditions, promising a revolutionary step forward in healthcare technology. Avant Technologies and Ainnova's partnership continues to push the boundaries of AI-driven early disease detection and preventive health measures.
